Wall Street Journal -
20 Nov 2014 02:58
A look at the partnership of Valeant CEO Michael Pearson and activist investor William Ackman in their failed $53 billion bid to acquire Allergan shows that the two men didn't always see eye to eye.
Share this Article
Comment on this Article
Please to comment